The Medicine Maker / Issues / 2017 / Articles / Jun / Smashing the Stigma with Science
Manufacture Business Practice Standards & Regulation Small Molecules Trends & Forecasts Regulation & Standards Small Molecules

Smashing the Stigma with Science

Cannabis can be a turn off for investors, but Neil Mahapatra and his investment firm are showing the world that there’s nothing to fear – and much to potentially gain – through a collaboration with Oxford University.

By Neil Mahapatra, Stephanie Vine 06/21/2017 1 min read

Share

A Career in Cannabinoids Cannabis Complex Smashing the Stigma with Science A View From the Biosynthetic Bridge Forming a Society for Cannabinoids Enhancing Endocannabinoid Signalling

About the Author(s)

Neil Mahapatra

Neil Mahapatra is Managing Partner of UK investment firm Kingsley Capital Partners, which established Oxford Cannabinoid Technologies in conjunction with a large-scale research programme with Oxford University.

More Articles by Neil Mahapatra

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

Recommended

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute